The Predictive Power of 11%: Is T-DXd’s pCR Gain Enough for Long-Term Benefit?

An 11% increase in pCR — but is it enough to predict long-term benefit? Drs. Pegram and Iyengar explore whether DESTINY-Breast11’s results will translate into durable survival gains for HER2+ early-stage breast cancer.